Isoflurane
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Isoflurane: From Inhaled General Anesthesia to Prinzmetal Angina
One-Sentence Summary
Isoflurane is a volatile (inhaled) general anesthetic. The supplied data does not include its approved indication text. The TxGNN model predicts it may be effective for Prinzmetal angina (score 99.67%), but no clinical trials and no publications currently support this specific prediction, so it is a model-only hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the supplied US label data (inhaled general anesthetic) |
| Predicted New Indication | Prinzmetal angina |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 7 (includes ANDA generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, isoflurane is a volatile anesthetic with vasoactive effects. Its efficacy as an anesthetic is established, and it may mechanistically influence vascular tone, which is relevant to vasospastic angina.
This link is speculative. The data supplied does not show isoflurane being evaluated as a treatment for vasospastic angina, and no mechanism could be verified. The prediction rests on the model score alone.
There is also a practical concern. An inhaled anesthetic given under monitored conditions is hard to reconcile with a chronic, recurrent condition like Prinzmetal angina, which is usually managed with outpatient oral therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA074502 | Isoflurane (Piramal Critical Care) | Liquid | Not specified in supplied data |
| ANDA074416 | Isoflurane (Piramal Critical Care) | Liquid | Not specified in supplied data |
| ANDA216527 | Isoflurane (Shandong New Time Pharmaceutical) | Liquid | Not specified in supplied data |
| NDA017624 | FORANE (Baxter Healthcare) | Inhalant | Not specified in supplied data |
ANDA216527 appears twice in the source data and is shown once here.
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the queried database.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no trials, no literature and no verified mechanism (Evidence Level L5). An inhaled anesthetic is also an implausible fit for a chronic vasospastic condition.
To proceed, the following is needed:
- Mechanism of action data for isoflurane, plus a literature search focused on coronary vasospasm.
- Package insert warnings and contraindications, which are required for any safety screening.
- Route and setting feasibility analysis (inhaled, monitored administration versus chronic outpatient use).
Other predictions for this drug: Among the other predicted indications, migraine disorder has the strongest signal (Evidence Level L4, decision stage S1, “Research Question”). Preclinical work reports that inhalational anesthetics inhibit cortical spreading depression, and two versions of a case report describe status migrainosus treated with general anesthesia. It has no registered trials, and the safety, dose and setting are undefined. If this candidate is reprioritized, migraine is the better place to start.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.